Insider Transactions in Q3 2021 at Mirum Pharmaceuticals, Inc. (MIRM)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 29
2021
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+14.7%
|
-
|
|
Sep 29
2021
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+39.13%
|
-
|
|
Sep 29
2021
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+8.71%
|
-
|
|
Sep 29
2021
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+33.96%
|
-
|
|
Sep 29
2021
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
8,125
+42.41%
|
-
|
|
Sep 29
2021
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
21,875
+46.97%
|
-
|
|
Jul 09
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
99,325
-100.0%
|
$1,489,875
$15.81 P/Share
|
|
Jul 07
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
6,837
-6.44%
|
$102,555
$15.87 P/Share
|
|
Jul 06
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
49,239
-31.69%
|
$787,824
$16.2 P/Share
|
|
Jul 02
2021
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,599
-6.38%
|
$180,183
$17.01 P/Share
|